Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miglitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 9/20 | 1.00 |
| ▸ | MGAM known ✓ | O43451 | 3/20 | 1.00 |
| ▸ | GBA1 | P04062 | 5/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | LCT | P09848 | 1/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 0.88 |
| ▸ | GBA2 | Q9HCG7 | 13/20 | 0.68 |
| ▸ | UGCG | Q16739 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miglitol SCHEMBL15669407 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL9207953 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL7862967 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL5727959 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL20402709 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL6545551 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL23892585 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL15269512 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL682218 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL25887976 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31348 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-20260069550-A1 | TRANSDERMAL DELIVERY OF ANTIDIABETIC AGENTS | RITTENHOUSE CHRISTINE (US) | 2026-03-12 | — | — | US | claimed |
| EP-4705280-A1 | DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260056214-A1 | DIAGNOSING AND TREATING END-STAGE RENAL DISEASE (ESRD) IN OBESE SUBJECTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2026-02-26 | — | — | US | claimed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-12508301-B2 | Decorin for its use in the treatment of diabetes | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2025-12-30 | — | — | US | claimed |
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| EP-0638317-B1 | Pharmaceutical composition comprising glucosidase- and/or amylaseinhibitors, and a lipase inhibiting agent | HOFFMANN LA ROCHE (CH) | 2000-03-15 | — | — | EP | claimed |
| US-6031004-A | METFORMIN (2:1) FUMARATE AND METFORMIN (2:1) SUCCINATE; ANTIDIABETIC AND HYPOGLYCEMIC AGENTS; IMPROVED HANDLING, I.E. LOWER HYGROSCOPICITY, FREE-FLOWING, REDUCED COMPACTION SUSCEPTIBIITY, CORROSION RESISTANCE; IMPROVED TASTE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-02-29 | — | — | US | claimed |
| EP-0975343-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND ALPHA-GLUCOSIDASE INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | claimed |
| WO-1999045973-A1 | DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | claimed |
| US-5952356-A | TREATING DIABETES IN A MAMMAL WITH AN ACTIVE MATERIAL AND A GLUCOSIDASE INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | claimed |
| WO-1999029314-A1 | NOVEL SALTS OF METFORMIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1999026606-A2 | SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-06-03 | — | — | WO | claimed |
| WO-1999003478-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOCIDASE INHIBITOR | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-01-28 | — | — | WO | claimed |
| WO-1998057635-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND ALPHA-GLUCOSIDASE INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 1998-12-23 | — | — | WO | claimed |
| EP-0638317-A1 | Pharmaceutical composition | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-15 | — | — | EP | claimed |